Wellington Management Group LLP Takes Position in Eton Pharmaceuticals, Inc. $ETON

Wellington Management Group LLP purchased a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,283 shares of the company's stock, valued at approximately $328,000. Wellington Management Group LLP owned 0.09% of Eton Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Mink Brook Asset Management LLC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth about $6,071,000. Millennium Management LLC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth about $1,850,000. Two Sigma Investments LP acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth about $1,498,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Eton Pharmaceuticals by 421.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 89,664 shares of the company's stock worth $1,194,000 after purchasing an additional 72,464 shares during the last quarter. Finally, Barclays PLC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth about $731,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eton Pharmaceuticals

In related news, insider David Krempa sold 16,977 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $14.92, for a total value of $253,296.84. Following the transaction, the insider owned 629,669 shares in the company, valued at approximately $9,394,661.48. This trade represents a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James R. Gruber sold 39,082 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $16.16, for a total transaction of $631,565.12. Following the completion of the transaction, the chief financial officer owned 205,299 shares in the company, valued at $3,317,631.84. The trade was a 15.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 75,713 shares of company stock worth $1,178,031 in the last 90 days. 16.03% of the stock is currently owned by insiders.

Eton Pharmaceuticals Trading Down 1.1%

Shares of ETON stock traded down $0.20 during trading hours on Friday, hitting $17.67. 286,782 shares of the company were exchanged, compared to its average volume of 285,878. The firm has a market cap of $473.91 million, a PE ratio of -110.44 and a beta of 1.10. Eton Pharmaceuticals, Inc. has a 1 year low of $4.52 and a 1 year high of $21.48. The company has a quick ratio of 1.16, a current ratio of 1.77 and a debt-to-equity ratio of 1.14. The firm has a fifty day moving average of $15.73 and a 200 day moving average of $15.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%.The company had revenue of $18.93 million for the quarter, compared to analysts' expectations of $16.71 million. Analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. B. Riley reaffirmed a "buy" rating and set a $26.00 price target (up from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th. Wall Street Zen cut shares of Eton Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $35.00 price objective (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Eton Pharmaceuticals has a consensus rating of "Buy" and an average target price of $29.67.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.